The thrombosis-related diseases are one of the leading causes of illness and death in the
general population, and despite significant improvements in long-term survival due to …

Non-vitamin K antagonist oral anticoagulants (NOACs) should be the preferred
anticoagulant strategy for preventing ischemic stroke in patients with atrial fibrillation (AF) at …

Relatively little is known about the influence of extreme body weight on the
pharmacokinetics (PK), pharmacodynamics (PD), efficacy, and safety of drugs used in many …

Introduction Recent studies have indicated that the dosage of LMWH in patients with specific
weights may be controversial. Therefore, we conducted a meta-analysis to explore an …

In clinical practice, direct oral anticoagulants (DOACs) are increasingly used for venous
thromboembolism treatment and prevention. A substantial proportion of patients with venous …

Objectives Obesity is associated with increased risks of atrial fibrillation (AF) and venous
thromboembolism (VTE) for which anticoagulation is commonly used. However, data on the …

Low molecular weight heparins (LMWH) and anti-Xa direct oral anti-coagulants (DOACs)
are recommended for the long-term treatment of cancer-associated thrombosis (CAT) based …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for the treatment of
venous thromboembolism (VTE) and for stroke prevention in atrial fibrillation (AF). However …

Objective Several trials had compared the efficacy and safety between non-vitamin K
antagonist oral anticoagulants and warfarin for acute venous thromboembolism, but the …

Direct oral anticoagulants (DOACs) are commonly used oral factor Xa inhibitors in recent
years. However, in some special clinical situations, the appropriate use of these …